PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

Final random-forest-based models outperformed all publicly available risk scores on internal and external test sets.

PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer," (1) demonstrating clinical validation ...

Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial We trained and tested ML systems ...

Senhwa Biosciences raises $16M to advance AI-powered drug discovery, accelerate cancer treatment trials, and expand machine ...

Bottom line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), ...

What are the benefits and challenges of using multiomics approaches to discover cancer biomarkers? Multiomics means that scientists are measuring more than one class of analyte, such as DNA, RNA, or ...

TrialTranslator uncovers the survival gap for high-risk patients and offers a path to better cancer research. Study: Evaluating generalizability of oncology trial results to real-world patients using ...

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...

We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) ...